Activity of Tepotinib in Hepatocellular Carcinoma With High-Level MET Amplification: Preclinical and Clinical Evidence
JCO Precision Oncology · 2024-02 · (8)
DOI: 10.1200/po.23.00328 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2024-02. Verfasst von Shukui Qin und 11 weiteren Autor:innen. Beteiligte Einrichtung: PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Piperidines, Pyridazines. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben.
Abstract (Originalsprache)
PURPOSE MET amplification ( METamp) has been reported in 1%-5% of patients with hepatocellular carcinoma (HCC) and may be sensitive to MET inhibition. Tepotinib, a selective MET inhibitor, has shown promising activity in HCC with MET overexpression. We investigated the preclinical and clinical activity of tepotinib in HCC with METamp ( MET gene copy number [GCN] ≥5), including high-level METamp ( MET GCN ≥10). METHODS Preclinical antitumor activity of tepotinib 100 mg/kg (orally, days 1-5, every 7 days, 3-5 weeks; 3-12 replicates) was evaluated according to METamp status, as determined using the nCounter platform (NanoString), in 37 HCC patient-derived xenografts (PDXs) in immunodeficient mice. Clinical outcomes were evaluated in patients with METamp by fluorescence in situ hybridization who received tepotinib 500 mg (450 mg active moiety) in two phase Ib/II trials in HCC with MET overexpression. RESULTS Across the PDX models, tepotinib induced complete or near-complete tumor regression in the only two models with high-level METamp. Median tumor volume reductions were 100% and 99.8% in models with MET GCN 47.1 and 44.0, respectively. Across the two clinical trials, 15/121 patients had METamp. Disease control was achieved by 11/15 patients with METamp (complete response [CR], n = 1; partial response [PR], n = 4; stable disease [SD], n = 6) and 4/4 with high-level METamp (CR, n = 1; PR, n = 2; SD, n = 1). All three patients with high-level METamp and objective response received treatment for >1 year, including one patient who received first-line tepotinib for >6 years. CONCLUSION High-level METamp may be an oncogenic driver in HCC that is sensitive to MET inhibitors such as tepotinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, China.
- Cancer Center of Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, China.
- Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
- Groupe Hospitalier Haut-Lévêque, CHU Bordeaux, France.
- Hôpital Jean-Verdier, Bondy, France.
- Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea.
ORCID-Profile: Shukui Qin, Ho Yeong Lim, Joachim Albers, Andreas Johne, Sandrine Faivre
Zitieren
APA
Qin, S., Pan, H., Blanc, J. F., Grando, V., Lim, H. Y., Chang, X. Y., O'Brate, A., Stroh, C., Friese-Hamim, M., Albers, J., Johne, A., & Faivre, S. (2024). Activity of Tepotinib in Hepatocellular Carcinoma With High-Level MET Amplification: Preclinical and Clinical Evidence. JCO Precision Oncology. https://doi.org/10.1200/po.23.00328
Vancouver
Qin S, Pan H, Blanc JF, Grando V, Lim HY, Chang XY, et al. Activity of Tepotinib in Hepatocellular Carcinoma With High-Level MET Amplification: Preclinical and Clinical Evidence. JCO Precision Oncology. 2024. doi:10.1200/po.23.00328
BibTeX
@article{Qin2024,
author = {Qin, Shukui and Pan, Hongming and Blanc, Jean Frédéric and Grando, Véronique and Lim, Ho Yeong and Chang, Xin Ying and O'Brate, Aurora and Stroh, Christopher and Friese-Hamim, Manja and Albers, Joachim and Johne, Andreas and Faivre, Sandrine},
title = {Activity of Tepotinib in Hepatocellular Carcinoma With High-Level MET Amplification: Preclinical and Clinical Evidence},
journal = {JCO Precision Oncology},
year = {2024},
number = {8},
doi = {10.1200/po.23.00328}
}
EUVIMED